Phenotype and Functional Properties of Monocytes from Patients under Laquinimod, a Novel Oral Therapy for the Treatment of Multiple Sclerosis

被引：0

作者：

Stasiolek, Mariusz

Linker, Ralf

Gaupp, Stefanie

Thone, Jan

Nisimov, Liat Hayardeny

Gold, Ralf

机构：

来源：

NEUROLOGY | 2011年 / 76卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：A134 / A134

页数：1

共 50 条

[1] Oral laquinimod treatment in multiple sclerosis
Fernandez, O.
NEUROLOGIA, 2011, 26 (02): : 111 - 117
[2] Oral laquinimod therapy in relapsing multiple sclerosis
Preiningerova, Jana
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (07) : 985 - 989
[3] Changes in Immune Parameters Following Commencement of Laquinimod, a Novel Oral Therapy for the Treatment of Multiple Sclerosis
Lund, Brett T.
Stasiolek, Mariusz
Kelland, Eve E.
Gaupp, Stefanie
Gilmore, Wendy
Linker, Ralf
Gold, Ralf
Weiner, Leslie P.
NEUROLOGY, 2011, 76 (09) : A139 - A139
[4] Oral laquinimod for treatment of relapsing-remitting multiple sclerosis
Weiner, Howard L.
LANCET NEUROLOGY, 2008, 7 (08): : 672 - 673
[5] Profile of oral laquinimod and its potential in the treatment of multiple sclerosis
West, Matthew S.
Miravalle, Augusto
DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2011, 1 : 25 - 32
[6] Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study
Stasiolek, Mariusz
Linker, Ralf A.
Hayardeny, Liat
Bar Ilan, Oren
Gold, Ralf
IMMUNITY INFLAMMATION AND DISEASE, 2015, 3 (02): : 45 - 55
[7] Laquinimod treatment is associated with specific modulation of monocyte co-stimulatory phenotype in multiple sclerosis patients
Stasiolek, M.
Linker, R.
Gaupp, S.
Nisimov, L. Hayardeny
Gold, R.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S198 - S198
[8] Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis
Thoene, Jan
Gold, Ralf
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (03) : 365 - 370
[9] Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis (review)
Boyko, A. N.
Gusev, E. I.
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 93 - 99
[10] Oral treatment with laquinimod reduces development of active MRI lesions in relapsing multiple sclerosis
Polman, C
Barkhof, F
Sandberg-Wollheim, M
Linde, A
Nederman, T
JOURNAL OF NEUROLOGY, 2004, 251 : 53 - 53

← 1 2 3 4 5 →